Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $52
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger maintains a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX), but lowers the price target from $60 to $52.
August 04, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a 'Buy' rating on Pacira BioSciences but lowers the price target from $60 to $52.
The news is directly related to Pacira BioSciences. While the 'Buy' rating is maintained, the lowering of the price target might indicate a potential decrease in the short-term stock price. However, the overall impact is neutral as the 'Buy' rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100